Introduction
Urinary trypsin inhibitor (UTI) is produced as a light chain of inter-α-inhibitor (IαI) by liver cells (1) . UTI is a 40 kDa sulfated glycoprotein comprised of several structurally and functionally distinct domains (2) . We have examined specific binding sites for UTI in certain cells (3) (4) (5) (6) (7) . Cell-binding experiments indicated that not only neoplastic cells (human choriocarcinoma SMT-cc1 [3] , human chondrosarcoma HCS-2/8 [6] , human promyeloid leukemia U937 [3, 4] , and murine Lewis lung carcinoma 3LL cells [3] ) but also non-neoplastic cells (human neutrophils [3] , human umbilical vein endothelial cells [HUVEC] [4] , fibroblasts [5] , and myometrial cells [7] ) have specific binding sites for UTI on their cell surface. UTI is bound to specific binding sites that are incompletely saturated. However, UTI-binding sites on the cell surface of U937 and neutrophils were completely saturated with endogenous UTI when these cells are cultured in the presence of 10 % fetal calf serum (FCS) (3) . A growing body of evidence has implicated that at least two types of binding sites (a 40 kDa on tumor necrosis factor (TNF)-α-or phorbol myristate acetate (PMA)-induced stimulation of uPA in these cells was studied (4) . UTI reduced the secretion of uPA in some cells (SMT-cc1, HCS-2/8, and 3LL cells) treated with PMA (3). On the other hand, incubation of U937 cells and HUVEC with UTI had no effect on the ability of PMA to stimulate cell-associated uPA expression (4) . However, induction of uPA expression by TNF-α was efficiently inhibited when the U937 and HUVEC were incubated with UTI (4) . One may estimate that the disparity is due to the difference of signaling cascades in cells used in the experiments.
Whereas both of these UTI-BPs appear to mediate binding to UTI, it is not known how two types of UTI-BPs may interact with UTI or if they mediate signals for UTI following ligation by the different domains within the UTI molecule. The purpose of this study was to evaluate further structure-function relationship of UTI by comparing interaction of truncated polypeptides with cells. UTI is structurally and functionally organized into distinct domains; therefore, we utilized purified proteins encompassing its three major domains, amino-terminal domain (N-domain), chondroitin-4-sulfate (C4S) side chain, and carboxyl-terminal domain (C-domain; an active protease inhibitor domain), to assess interactions between UTI and cell-associated UTI-BPs. To identify the structural determinants on UTI required for cell association and regulation of the uPA-dependent signal transduction, UTI derivatives (non-glycosylated UTI [NG-UTI] and the carboxyl-terminal fragment of UTI ) were produced (see Figure 1 ). We describe experiments designed to ask whether the UTI-BPs are capable of delivering an UTI-dependent modulation of uPA expression. We have examined two types of experimental situation: binding capacity of UTI to the cells or its binding sites, and responses to UTI in cells stimulated with
Materials and Methods

Materials
UTI was purified to homogeneity from human urine. A highly purified preparation of human UTI was kindly supplied by Mochida Pharmaceutical Co., Tokyo, Japan. The carboxyl-terminal fragment of UTI (HI-8) was purified as previously described (2) (3) (4) (5) (6) 9, 13, 14) . The isolation of cartilage-derived link protein (LP) has been described in detail elsewhere (6, 19) . Chondroitinase ABC was purchased from Sigma Chemical Co. (St. Louis, MO). Hyaluronidase (Streptomyces hyalurolyticus, #100740), hyaluronic acid (Mr 1090 kDa), chondroitin-4-sulfate (C4S; Mr 21 kDa), chondroitin-0-sulfate (C0S; Mr 6 kDa), dermatan sulfate (DS; Mr 18 kDa), and heparin (Mr 13 kDa) were kindly supplied by Seikagaku Kogyo (Tokyo, Japan). All other chemicals were of reagent grade or better and were purchased from major suppliers.
Treatment of UTI with chondroitinase ABC: preparation of non-glycosylated
UTI (NG-UTI)
UTI (1 mg/ml) was treated for 2 h at 37 °C with 50 µg/ml chondroitinase ABC in 50 mM phosphate buffer, 10 mM EDTA, 10 mM NaN3, pH 7.2. A Sephadex
Purification of the urinary trypsin inhibitor-binding proteins (UTI-BPs)
The UTI-BPs were purified by UTI-coupled Sepharose 4B and molecular sieve chromatography as described previously (3, 5) . Affinity chromatography and reverse-phase high performance liquid chromatography were used to purify soluble UTI specific binding proteins from the lysates of HCS-2/8 as described previously (3, 5, 6) . Two binding sites for UTI (UTI-BP40 and UTI-BP45) have been purified. UTI-BP40 was identified as a truncated form of human cartilage LP (6) .
Preparation of antibodies
Rabbit polyclonal antibodies raised against UTI-BP, LP, or LP synthetic peptide (LPpep-N) were prepared in our laboratory (6) . Briefly, to generate anti-LP peptide antibodies, two synthetic oligopeptide sequences, 112 VFLKGGSDSDAS 123 (NH2-terminal fragment of LP) and 231 TVPGVRNYGFWDKDKS 246 (COOH-terminal fragment of LP), corresponding to the NH2-terminal domain and the COOHterminal domain of human LP molecule, respectively, were selected. Antisera against LP synthetic oligopeptides (anti-LPpep-N and anti-LPpep-C) were obtained from rabbits immunized four times with 0.2 mg peptide conjugated with keyhole limpet hemocyanin together with Freund's adjuvant (6) .
Radioactive iodination of UTI and its derivatives
UTI was radioiodinated with carrier-free Na-125 I. Briefly, 5 µg of UTI was placed in a conical microvial and then dissolved in 20 µl of 50 mM sodium bicarbonate.
Tris-HCl buffer (20 µl each of 50 mM and 500 mM, pH 7.4), 1 mCi of carrier-free Na-125 I, and 5 µg of lactoperoxidase were added to the iodination vial. The 
Cell lysate preparation
Cells (2 x 10 8 ) preincubated with serum-free medium overnight were treated with PBS containing protease inhibitor cocktail supplemented with hyaluronidase (10 µg/ml) for 15 min at 37 °C (3, 5, 6) . At the end of the incubation, the supernatant was recovered for hyaluronidase-soluble phase.
The pelleted cells were extracted in 4 ml lysis buffer (10 mM Tris-HCl, pH 8.1, twice each with serum free medium supplemented with 0.1 % BSA. The cells were maintained for overnight in serum free medium. Monolayers were cooled to 4 °C and washed twice with Tyrode's-Hepes solution containing 2 % BSA (washing buffer). The cells were then incubated at 4 °C for 2 h in binding buffer (150 mM NaCl, 10 mM HEPES, 2 mM CaCl2, 1 mM MgCl2, 2 % BSA, pH 7.8) containing various concentrations of 125 I-labeled UTI or NG-UTI (0-10 nM) and washed four times. The binding of 125 I-UTI to cells was then determined as previously described (7) . The contents of the wells were removed using 1N NaOH and radioactivity was measured using a γ-counter. Each experimental point was performed in at least duplicate wells. The nonspecific binding, determined as the percent of input counts bound in the presence of 1 µM unlabeled UTI, was approximately 9 % and was subtracted from all raw data to give the specific bound counts. In a parallel experiment, cells were incubated with 125 I-UTI (1 nM) for 2 h at 4 °C in the presence or absence of several competitors, and then washed four times.
Ligand-and Immuno-blotting procedures
Cell extracts (detergent phase) and supernatants (hyaluronidase-soluble phase)
were tested for UTI-BP40 and UTI-BP45 by Western blot or by ligand-blotting with labeled ligands. For ligand blotting, purified UTI-BPs, LP, hyaluronidasesoluble or detergent phase separated membrane fractions were run in 10 % SDS-PAGE under nonreducing conditions, electroblotted to PVDF membranes (BioRad) and blocked for 2 h at 23 °C in TBS contining 2 % BSA. The filters were then incubated for 16 h at 4 °C in the presence of 1 nM iodinated ligand in binding buffer, washed three times, and autoradiographed for 18 h to 2 days.
Each band was cut from the membrane and radioactivity was measured using a γ-counter. The assays were performed with duplicate samples. The nonspecific binding was subtracted from all raw data to give the specific bound counts.
In a parallel experiment, Western blotting with a rabbit polyclonal antibodies raised against LP was performed as described previously (6, 20) .
Determination of plasminogen activator activity
Plasminogen activator (PA) activity in the cell-conditioned media (100 µl) was quantitated utilizing a functional assay for plasmin. Medium (100 µl) was then incubated for 3 h in buffer A (PBS containing plasminogen [0.165 U/ml] and S-2251 [0.5 mM]) as the chromogenic substrate of plasmin. In a parallel experiment, after the monolayer cells were washed, the medium was replaced with buffer A and incubated for 1 h to determine the cell-associated PA activity.
The amount of p-nitroaniline released was determined spectrophotometrically at 405 nm. Each assay was run with a plasminogen-free blank.
Statistical analysis
The data presented are the mean of triplicate determinations in one representative experiment unless stated otherwise. Data are presented as mean ± standard deviation (SD). All statistical analysis was performed using StatView for Macintosh. The Mann-Whitney U test was used for the comparisons between different groups. P less than 0.05 was considered significant. 
The kinetics of UTI binding to UTI-BP40 and UTI-BP45
We have previously demonstrated that there are at least two types of UTI binding sites, the UTI-BP40 and the UTI-BP45, on the surface of certain cells, and binding of UTI to cells is specifically inhibited by monoclonal antibodies (mAbs) 4G12 and 8H11, which recognize the N-domain of UTI, demontrating that UTI binds to the cells via the N-domain of UTI (3, 5) .
We first tested for the presence of UTI-BPs in HCS-2/8 cells by a ligandblotting analysis. Affinity purified UTI-BP40 and UTI-BP45 proteins prepared from HCS-2/8 cell lysate (6) were used as a positive control in the identification. To identify the structural determinants on UTI required for cell association, NG-UTI and HI-8 were produced and used as 125 I-labeled ligands.
We incubated 125 I-labeled ligands with affinity-purified UTI-BP40 or UTI-BP45 transferred to PVDF paper in the presence or absence of an excess amount of unlabeled compounds. We found that the cells contain, in addition to a 40 kDa UTI-BP40, also a 45 kDa UTI-BP45 (Figure 2 (Fig. 3-B) was comparable to that of 125 I-UTI to UTI-BP40 (Fig. 3-A) .
Competitive binding experiments using in vitro ligand-blot assay demonstrated that the binding of 125 I-UTI to UTI-BP40 was completely blocked by a 100-fold molar excess unlabeled UTI, NG-UTI, anti-LPpep-N antibody, while this binding was essentially unaffected by HI-8 and any glycosaminoglycans including fluid-phase, soluble C4S, chondroitin-0-sulfate (C0S), hyaluronic acid (HA), dermatan sulfate (DS), or heparin at concentrations of these compounds as high as 100 µg/ml. In contrast, the binding of 125 I-UTI to UTI-BP45 (Fig. 3-C ) was inhibited about 25 % or 85 % by soluble C4S at concentrations of 10 µg/ml or 100 µg/ml, respectively, while the binding of 125 I-UTI to UTI-BP45 was essentially unaffected by a 500-fold molar excess NG-UTI, HI-8, or anti-LPpep-N antibodies. The inhibitory effects of anti-LPpep-N antibodies (10 µg/ml) and soluble C4S (10 µg/ml) were not additive. We confirmed again that 125 I-NG-UTI did not bind to UTI-BP45 (Fig. 3-D) . Taken together, the results strongly suggest that the N-domain of UTI is important for contact with UTI-BP40 and that UTI-BP45, a protein that was distinct from UTI-BP40, is another binding protein (or receptor) for the C4S side chain within the UTI molecule. As shown in Figure 6 , an 500-fold molar excess UTI or NG-UTI inhibited the 125 I-NG-UTI binding by >95 % (Fig. 6-B) . Likewise, excess UTI completely competed against the binding of the 125 I-UTI, however, excess NG-UTI (upon an excess of 5,000 nM) competed for about 50 % of the 125 I-UTI binding (Fig. 6-A) . 
The favored pathway for UTI action: UTI-BP45 mediates UTI-dependent signal transduction
As a final question, we tested whether UTI-mediated suppression of PMAstimulated up-regulation of uPA was dependent on either UTI-BP40 or UTI-BP45.
The amount of uPA expressed on the cells stimulated with 1.0 µM phorbol ester (PMA) was maximal at 6-9 h of incubation (unpublished data). As expected (Figure 7) , UTI significantly inhibited PMA-induced uPA expression during a 7-h incubation. Unlike UTI, NG-UTI failed to abrogate PMA-induced uPA expression, suggesting that the C4S side chain within the UTI molecule may play a role in UTI-dependent signal transduction. with regard to size, affinity, cross-reactivities to antibodies, and ligand specificity (3, 5, 6) . Only in the case of human myometrial cells, however, the molecular mass of LP is considered to be approximately 45 kDa (7), which corresponds to intact LP.
Our studies of truncated UTI led us to conclude that 1) the N terminus is a critical domain for UTI binding to UTI-BP40 or LP and the C4S-side chain of UTI forms the key determinants for the high affinity specific binding of UTI to UTI-BP45, demonstrating that UTI-BP40 recognizes the N-domain of UTI and UTI-BP45 consists of a binding portion for C4S-side chain within the UTI molecule, 2) either the N-terminal domain or the C4S-side chain can bind cells even in the absence of the other, demonstrating that the interaction between UTI and UTI-BP40, and the interaction of UTI and UTI-BP45, have been considered to occur independently of one another, 3) since UTI can bind UTI-BP40 (Kd = ~250 nM) and UTI-BP45 (Kd = ~10 nM), we believe that UTI binds initially to UTI-BP45 and subsequently to UTI-BP40, and 4) although essential for binding, either the N terminus alone or C4S-side chain alone is not sufficient for UTI-dependent suppression of PMA-activated up-regulation of uPA. This function is inhibited by reagents that were shown to prevent binding of UTI to either the UTI-BP40 or UTI-BP45. These results suggest that UTI must bind to both of the UTI-BPs to suppress uPA up-regulation.
It has been established that UTI binding to the cells may result in inhibition of PKC translocation (4), abrogation of MAP kinase activation (8) and subsequently suppression of PMA-or TNF-α-induced up-regulation of uPA expression (4) . In this study, we postulate that the binding of UTI to UTI-BP40 does not initiate UTI signaling because UTI-BP40 lacks the cytoplasmic domain which is required to recruit appropriate adapter molecules. UTI-BP40 seems to help recognition of UTI and/or UTI-UTI-BP45 complexes either by guiding a favorable accumulation of UTI into cell-associated extracellular matrix.
Therefore, UTI-BP40 may act as a molecular trap for UTI or a decoy target for UTI when C4S-side chain is cleaved by certain enzymes such as hyaluronidase or chondroitinase.
In contrast, UTI-BP45 should be considered as an active participant in the complexes, rather than simply as an UTI-binding molecule. The ability of UTI-BP45 to directly bind C4S side chain of UTI and then generate signals indicates that this molecule might play a key role in UTI-mediated signal transduction. We consider that the term "binding protein" may be an inappropriate designation, and propose to refer to the UTI-BP45 as a "UTI receptor".
Based on these findings, we postulate that UTI-mediated inhibition of tumor cell invasion and metastasis appears to consist of at least two pathways, 
